Catecholaminergic polymorphic ventricular tachycardia: important messages from case reports

Europace. 2011 Jan;13(1):11-3. doi: 10.1093/europace/euq330. Epub 2010 Sep 17.
No abstract available

Publication types

  • Comment
  • Editorial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adrenergic beta-Antagonists / therapeutic use
  • Animals
  • Anti-Arrhythmia Agents / therapeutic use*
  • Calcium Channel Blockers / therapeutic use
  • Catecholamines / metabolism
  • Defibrillators, Implantable*
  • Flecainide / therapeutic use*
  • Genetic Counseling
  • Genetic Testing
  • Germ-Line Mutation / genetics*
  • Humans
  • Mice
  • Ryanodine Receptor Calcium Release Channel / drug effects
  • Ryanodine Receptor Calcium Release Channel / genetics*
  • Tachycardia, Ventricular / genetics
  • Tachycardia, Ventricular / prevention & control
  • Tachycardia, Ventricular / therapy

Substances

  • Adrenergic beta-Antagonists
  • Anti-Arrhythmia Agents
  • Calcium Channel Blockers
  • Catecholamines
  • Ryanodine Receptor Calcium Release Channel
  • Flecainide

Supplementary concepts

  • Polymorphic catecholergic ventricular tachycardia